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Aims: The aim of this study is to examine the effects of taurine supplementation on homocysteine (Hcy) metab-
olism and liver injury in rats fed a choline-deﬁcient diet.
Main methods: Thirty rats were divided into three groups (n = 10), to receive one of the following diets for
4 weeks: control diet (C), choline-deﬁcient diet (CDD), or choline-deﬁcient diet supplemented with taurine
(CDDT). The CDD and the CDDT consisted of AIN-93 without the recommended choline content of 2.5%, and
the CDDT was supplemented by the addition of 2.5% taurine.
Key ﬁndings: Four weeks of ingesting a CDD resulted in a signiﬁcant increase in plasmaHcy (50%) as well as a de-
crease in liver S-adenosylmethionine (SAM) concentration and S-adenosylmethionine/S-adenosylhomocysteine
ratio. No changes were found in plasma methionine and cysteine plasma levels compared to control group.
Four weeks of ingesting a CDD also caused a signiﬁcant (P b 0.05) increase in hepatic total fat, hepatic
malondialdehyde (MDA), and plasma alanine aminotransferase (ALT) levels. In addition, reduced hepatic
glutathione (GSH) levels and reduced/oxidized glutathione ratios (GSH/GSSG)were found in rats fed a CDD com-
pared to controls. Taurine supplementation of the CDDnormalized genes involved in the remethylation pathway,
BHMT and CHDH, which were impaired by CDD alone. However, taurine supplementation failed to prevent
CDD-induced Hcy metabolism disturbances and hepatic injury. Also, taurine added to CDD caused de-
creased expression of PEMT, CHKa, and CHKb, key genes involved in phosphatidylcholine (PC) synthesis
and liver fat accumulation.
Signiﬁcance: Taurine supplementation failed to ameliorate impaired Hcymetabolism and liver injury caused
by CDD intake.© 2014 Elsevier Inc. All rights reserved.Introduction
In the last few years, elevated blood concentration of homocysteine
(Hcy) has been considered a risk factor for the development of cardio-
vascular disease (Steed and Tyagi, 2011). Numerous studies have also
related hyperhomocysteinemia (HHcy) to several diseases, such as neu-
rodegenerative disease, diabetes, renal dysfunction, fatty liver disease
and others (Oulhaj et al., 2010; Wijekoon et al., 2005; Taes et al., 2004).
Hcy is an amino acid formed exclusively by demethylation ofmethionine
(Deminice et al., 2013). In Hcy synthesis, S-adenosylmethionine (SAM)
acts primarily as a universalmethyl donor in the synthesis ofmethylated
compounds. Once formed, Hcy can be remethylated to formmethionineEducation, Faculty of Physical
ia Celso Garcia Cid, Pr 445 Km
l.: +55 43 36024564, +55 16by two parallel pathways, both of which may lower Hcy concentrations.
The betaine-homocysteine S-methyltransferase (BHMT) remethylation
pathway requires betaine, which is the methyl donor in this reaction
and is derived from dietary choline (Deminice et al., 2013; Brosnan
et al., 2007). Studies have shown that a choline-deﬁcient diet (CDD) im-
pairs methionine remethylation, increases Hcy levels (Setoue et al.,
2008) and promotes liver injury characterized by oxidative stress and
fatty liver (Raubenheimer et al., 2006; Ueland, 2011).
As an end product of the transsulfuration pathway in Hcy metabo-
lism, taurine supplementation may play a crucial role in methionine
metabolism in the liver (Fig. 1). Taurine (2-minoethanesulfonic acid)
is a sulfur-containing amino acid synthesized endogenously from cyste-
ine or obtained by dietary components, especially ﬁsh and seafood
(Stipanuk and Ueki, 2011). Recently, taurine supplementation has
shown protective effects—such as antioxidant properties—to improve
insulin sensitivity and dyslipidemia, as well as fatty liver disease, in rat
models of obesity, diabetes type 2, and steatohepatitis (Balkan et al.,
2002; Rosa et al., 2014; Xiao et al., 2008). However, the effects of taurine
supplementation on Hcy metabolism disturbances and liver injury,
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Yang et al. (2009) demonstrated that taurine supplementation de-
creased Hcy through improved utilization of sulfur-containing amino
acids after alcohol administration. We hypothesized that taurine
supplementation may modulate the catabolism of Hcy through the
transsulfuration pathway and alleviate disturbances in methionine
metabolism caused by CDD intake. The aim of the present study was
to examine the effects of taurine supplementation on Hcy metabolism
and hepatic injury in rats fed a CDD.
Methods
Rats and treatment
Thirty male Wistar rats (initial weight ~140 g) were obtained from
the Faculty of Medicine of Ribeirao Preto Central Animal Care. All proce-
dures were approved by the Ethics Committee for Animal Use of the
same institution and were in accordance with the Guidelines of the
COBEA (Brazilian College of experiments with animals). The rats were
housed in individual cages on a 12-h-light/-dark cycle at a mean tem-
perature of 22 °C and were randomly assigned to into three groups of
10 rats each: control (C); choline-deﬁcient diet (CDD); choline-
deﬁcient diet with taurine supplementation (CDDT). C group was fed
with AIN-93 standard diet proposed by Reeves et al. (1993) composed
by 2.5% of choline. The CDD and the CDDT consisted of AIN-93 without
the recommended choline content of 2.5%, and the CDDT was supple-
mented by the addition of 2.5% taurine. The rats had free access to
food throughout the 4 weeks. Food intake wasmeasured daily to assess
food, choline and taurine consumption. Body weight was measured
twice a week to determine the weight gain.
Tissue preparation
After four weeks of experiment, rats were anesthetized with an
intra-peritoneal injection of sodium pentobarbital (65 mg/kg i.p.). Ani-
mals were sacriﬁced between 9 and 11 am. Blood was collected into
heparinized tubes, centrifuged and the plasma stored at−80 °C. A por-
tion of the liverwas freeze-clampedwith aluminum tongs pre-cooled in
liquid nitrogen, weighed and stored at −80 °C. All procedures were
performed under standard RNase-free conditions to avoid exogenous
RNase contamination.
Homocysteine and metabolites
Plasma and liver Hcy levels and sulfur-containing amino acids
were assayed by gas-chomatography (GC-FID, GC-17A Shimadzu®,
Kyoto, Japan) derivatized with commercially available kit EZ:Faast
Amino Acid Analysis (Phenomenex®). For SAM and SAH determina-
tions, freeze-clamped liver samples were homogenized in ice-cold
8% (wt./vol.) trichloroacetic acid and the homogenates centrifuged at
13,000 g for 5 min at 4 °C. The supernatants were analyzed by HPLC
(LC-20A Shimadzu®, Kyoto, Japan) using a Phenomenex® C18 column
equilibrated with 96% of buffer A (50 mmol/L NaH2PO4 containing
10 mmol/L heptanesulfonic acid at pH 3.2) and 4% acetonitrile. SAM
and SAH were separated by means of a gradient of 96–80% of buffer A
and 4–20% of acetonitrile for 25min. SAMand SAHpeakswere detected
at 258 nm and quantiﬁed using LC solution software (Shimadzu®,
Kyoto, Japan).
Indices of hepatic injury
Plasma alanine aminotransferase (ALT) activity was performed
using commercially available kit (Labtest, Lagoa Santa, Minas
Gerais, Brazil). Liver malondialdehyde (MDA) was determined by
HPLC (LC-20A Shimadzu®, Kyoto, Japan) according to Spirlandeli
et al. (2014). Hepatic reduced (GSH) and oxidized glutathione(GSSG) were performed as described by Rahman et al. (2006). Liver
total fat was determined by homogenizing 0.5 g of liver in 1.0mL of dis-
tilled water; 5 mL of chloroform–methanol (2:1) was added and the
tubes were thoroughly mixed. After centrifugation, the chloroform
phase was transferred to a pre-weighed tube, the extraction was
repeated twice and the chloroform phases were combined, evapo-
rated to dryness and re-weighed. The fat was re-suspended in
1 mL 1-propanol for the measurement of total liver triglycerides,
using commercially available kits from Labtest (Lagoa Santa, Minas
Gerais Brazil).
Gene expression
Total RNAwas isolated from 50mg of frozen liver using RiboPure Kit
(Ambion, part number AM 1924, USA) according to the manufacturer's
instructions. Total RNA was quantiﬁed by spectrophotometer at OD
260/280 (NanoDrop2000c, USA). The quality and integrity of the isolat-
ed RNA were assessed using agarose gel (1.2%). Additional DNase I
treatment (DNA-free Kit, Ambion, part number AM1906, USA) was
performed to remove contaminating DNA from isolated total RNA.
cDNA was synthesized from 1000 ηg of total RNA using High-capacity
cDNA Reverse Transcription Kit (Applied Biosystems, part number
4374966, USA). Quantitative real-time PCR was performed using 7500
Fast Real-time PCR System (Applied Biosystems, USA). The following
Taqman® Gene Expression Assays (Applied Biosystems, USA) were
used in this study: Rn00564517_m1 (Pemt), Rn00578255_m1 (Bhmt),
Rn00567215_m1 (Gnmt), Rn00560948_m1 (Cbs), Rn01644299_m1
(ChDh), Rn00567492_m1 (Chka), Rn00755199_g1 (Chkb), Rn00589584_
m1 (Pcyt 1a), and Rn00690933_m1 (cyclophilin A). The cycles for
PCR were as follows: one cycle of 95 °C for 20 s, 40 cycles of 30 s at
95 °C, 30 s at 60 °C. Each PCR assay was performed in triplicate.
Cyclophilin A was used as reference gene to normalize the reactions.
The relative quantitation was determined by the 2−ΔΔCT method.
Statistical analysis
Data were reported as means ± standard error. Groups were com-
pared by ANOVA one-way and post-test of Tukey to identify speciﬁc dif-
ferences between pairs of treatments using the SAS statistical package
(version 8.2). In all analyses, the level of signiﬁcance was set at P b 0.05.
Results
No differences in bodyweight gain, food intake, or liver weightwere
observed for the three groups during the 4-week experimental period.
As expected, choline and taurine intake were higher (P b 0.05) in
the C and CDDT groups, respectively, compared to the other groups
(Table 1).
CDD intake resulted in a signiﬁcant increase in plasma Hcy levels
(50%) as well as decreased liver SAM concentration (25%) and de-
creased SAM/SAH ratio (34%) (Fig. 1). No changes were observed in
plasmamethionine and cysteine in the CDDgroup compared to the con-
trol group. Four weeks of CDD intake also exacerbated hepatic injury, as
evidenced by a signiﬁcant (P b 0.05) increase in hepatic total fat hepatic
MDA and plasma ALT. In addition, reduced GSH and lower GSH/GSSG
ratio were found in rats fed CDD compared to controls Table 2. Supple-
mentation with taurine does not prevent Hcy metabolism disturbances
and hepatic injury induced by CDD.
We examined the abundance of genes involved in themetabolism of
Hcy and choline. CDD decreased the expression of genes involved in the
remethylation pathway (BHMT and CHDH) compared to control group.
Taurine supplementation reversed these perturbations. However, tau-
rine added to CDD resulted in decreased phosphatidylethanolamine
N-methyltransferase (PEMT) gene expression, as well as lower CHKa
and CHKb gene expression. This result was not found in C or CDD-fed
Fig. 1. PlasmaHcy levels (A); liver SAM (B); liver SAH (C) and SAM/SAH ratio in groups fedwith control (C), choline-deﬁcient (CDD) or taurine supplemented (CDDT) diets for fourweeks.
Values are presented as means ± standard error, n= 10. ab, means with different letters differ (P b 0.05; one-way ANOVA with post-test of Tukey).
45R. Deminice et al. / Life Sciences 105 (2014) 43–47rats (Fig. 2). No signiﬁcant difference in CBS, GNMT, and PCYT1AmRNA
expression was found between groups.Discussion
To the best of our knowledge, this is the ﬁrst study to examine the
effects of dietary taurine supplementation on Hcy metabolism and
markers of hepatic damage in rats fed a CDD. The major ﬁndings of
this investigation were: 1) CDD causes increases in plasma Hcy and
elevated indices of liver injury characterized by oxidative stress and
fat liver accumulation; 2) however, taurine supplementation did not
modulate catabolism of Hcy via transsulfuration pathway or alleviate
disturbances in liver caused by CDD intake; 3) alternatively, taurine
supplementation was able to normalize to control levels the abundance
of genes involved in the remethylation pathway, BHMT and CHDH; how-
ever, it failed to increase SAM availability, as well as to decrease Hcy
levels.
Hcy and taurine are both sulfur-containing amino acids sharing the
same biosynthetic pathway. Taurine is an end product in sulfur-amino
acid catabolism through the methionine and cysteine pathways in the
liver (Yang et al., 2009). However, themechanismbywhich taurine sup-
plementation modulates methionine metabolism and Hcy concentra-
tion is poorly understood. Also, the effects of taurine supplementationTable 1
General characteristics of the rats fed control (C), choline-deﬁcient (CDD) or taurine
supplemented (CDDT) diet for four weeks.
C CDD CDDT
Body weight gain (g) 187.3 ± 16.9 188.9 ± 18.0 182.2 ± 16.7
Food intake (g/day) 22.3 ± 1.2 21.5 ± 1.5 23.2 ± 1.4
Liver weight (% body weight) 2.1 ± 1.1 3.6 ± 0.4 3.2 ± 0.6
Choline intake (g/day) 0.56 ± 0.1 – –
Taurine intake (g/day) – – 0.58 ± 0.1
Values are presented as means ± standard error, n = 10.on decreased Hcy concentration remain controversial. Studies have
shown that taurine supplementation decreases Hcy in different condi-
tions (Yang et al., 2009; Zulli et al., 2009). On the contrary, some authors
report that taurine supplementation has no effects on Hcy metabolism
(ElMesallamy et al., 2010). Yang et al. (2009) found that taurine supple-
mentation (2 g/kg bodyweight) prevented increased plasma Hcy in rats
ingesting alcohol over 4 weeks (Table 2). Zulli et al. (2009) demonstrat-
ed that taurine supplementation (2.5%) in rabbits inhibited the increase
in plasma methionine and Hcy level induced by a rich-cholesterol-
methionine diet compared to control group. These authors attributed
the action of taurine to its capacity for diminishing methionine absorp-
tion and HHcy as a consequence. In contrast, El Mesallamy et al.
(2010) demonstrated that rats fed a high-fructose diet developed
HHcy, which was not reversed by taurine supplementation (300 mg/
kg/day) over 35 days. Taurine is an end product of transsulfuration,
and some studies have proposed that taurine supplementation may
modulate this pathway (Yang et al., 2009). Our results demonstrated
no changes in CBS gene expression, a key enzyme in transsulfuration
pathway. Hepatic levels of cysteine, serine and GSH—important prod-
ucts of transsulfuration pathway—were also unchanged in rats fed
CCDT compared to CDD group. These results together demonstrated
that taurine supplementation was unable to increase Hcy catabolism
through transsulfuration pathway; these results partially refute our
original hypothesis.
Alternatively, our results suggest that taurine supplementation par-
tially modulates methioninemetabolism impaired by CDD intake at the
level of remethylation. We observed that CDD intake impaired methio-
ninemetabolismby decreasing SAMavailability and the SAM/SAH ratio,
leading to an elevated Hcy concentration in plasma and liver injury. The
SAM metabolic blockade may occur by reduced BHMT and CHDH gene
expression. CHDH catalyzes the conversion of choline to betaine, an im-
portant methyl donor. Once formed, betaine can be demethylated by
BHMT, a process that plays a major role in the overall conversion of
Hcy to methionine in the remethylation pathway (Cole et al., 2012).
Collinsova et al. (2006) found that in vivo inhibition of BHMT in mice
Fig. 2. Ametabolic interaction of Hcy, choline and taurine pathways (A). Relative mRNA expression (arbitrary units) analysis of genes related to methionine metabolism (B) and choline
metabolism (C) (ab, Means without a common letter differ, P b 0.05; one-way ANOVA with post-test of Tukey). Taurine supplementation was not able to modulate CβS and
transsulfuration pathway anddonot alleviate disturbances inmethioninemetabolismcausedby CDD intake. Alternatively, taurine supplementationwas able to normalize to control levels
the abundance of genes involved in the remethylation pathway, BHMT and CHDH; however, it failed to increase SAMavailability, aswell as to decreaseHcy levels. In addition, taurine added
to CDD resulted in decreased gene expression of PEMT, CHKa and CHKb, enzymes that are involved in choline metabolism. SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine;
PEMT, phosphatidylethanolamine N-methyltransferase; PE, phosphatidlyethanolamine; PC, phosphatidylcholine; CT, CTP:phosphorylcholine cytidylyltransferase; CBS, cystathionine
beta synthase; BHMT, betaine-homocysteine S-methyltransferase; GNMT, Glycine N-methyltransferase; CDO, cysteine dioxygenase.
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intake may reduce remethylation of methionine by BHMT (Fig. 2),
resulting in decreased SAM availability and increased Hcy levels
(Fig. 1). Taurine supplementation normalized to control levels the
abundance of CHDH and BHMT; however, it was unable to increase
SAM availability and the SAM/SAH ratio as well as to decrease Hcy
levels (Fig. 1). This alternative mechanism of taurine in modulate
remethylation pathway is a novelty and must be considered in future
studies.Table 2
S-containing amino acids and markers of liver injury in rats fed control (C), choline-
deﬁcient (CDD) or taurine supplemented (CDDT) diet for 4 weeks.
C CDD CDDT
S-containing amino acids metabolites
Plasma methionine (μmol/L) 50.7 ± 4.9 49.8 ± 5.1 54.7 ± 6.1
Plasma cysteine (μmol/L) 205.1 ± 11.8 263.2 ± 34.6 242.3 ± 31.7
Plasma folate (ng/mL) 24.9 ± 1.5a 31.3 ± 1.8ab 36.1 ± 4.1b
Plasma vitamin B12 (pg/mL) 3.4 ± 0.2 3.2 ± 0.2 3.3 ± 0.3
Liver Hcy (nmol/mg protein) 25.7 ± 3.3 28.3 ± 3.9 31.1 ± 4.6
Liver methionine
(μmol/mg protein)
0.23 ± 0.04 0.25 ± 0.06 0.28 ± 0.07
Liver cysteine (μmol/mg protein) 0.29 ± 0.05a 0.39 ± 0.09ab 0.41 ± 0.13b
Liver serine (μmol/mg protein) 0.46 ± 0.09 0.49 ± 0.14 0.48 ± 0.10
Liver injury
Liver MDA (nmol/g tissue) 3.9 ± 0.4a 4.8 ± 0.2b 5.1 ± 0.4b
Liver GSH (mmol/mg tissue) 3.8 ± 0.1a 3.2 ± 0.1b 3.6 ± 0.1ab
Liver GSH/GSSG 28.1 ± 4.1a 17.3 ± 2.0b 18.7 ± 2.8b
Plasma ALT (U/L) 47.8 ± 3.9a 69.4 ± 5.1b 72.3 ± 6.6b
Liver total fat (mg/g tissue) 76.1 ± 4.6a 115.3 ± 8.5b 111.1 ± 13.4b
Values are presented as means ± standard error, n = 10. ab, means in a row with
different letters differ (P b 0.05; one-way ANOVA with post-test of Tukey).Our non-beneﬁcial results of taurine supplementation are different
from those found in studies in fatty liver disease caused by a high-fat
diet (Chen et al., 2006; Chang et al., 2011), a high-cholesterol diet
(Park and Lee, 1998; Park et al., 2007), and a high-sucrose diet
(Gentile et al., 2007). These studies reveal several mechanisms related
to the beneﬁcial effects of taurineupon lipidmetabolismand liver injury
such as improving the conversion of cholesterol to acid formation; sup-
pression in triglycerides secretion by the liver; improvement of glucose
control and insulin signaling. The CDD, in addition to causing fat liver ac-
cumulation, oxidative stress and inﬂammation; very similar perturba-
tions caused by a high-fat, high-cholesterol and high-sucrose diets
(Chang et al., 2011; Gentile et al., 2007), also leads to an impaired me-
thionine metabolism and HHcy. Impaired methionine metabolism and
fatty liver caused by CDD are linked to phosphatidylcholine (PC) forma-
tion. In the present study, taurine added to CDD resulted in decreased
PEMT, CHKa, and CHKb gene expression, enzymes involved in PC syn-
thesis. In the liver, PC is synthesized through two routes (see Fig. 2):
1) the CDP–choline pathway, for which the substrate is dietary choline;
and 2) methylation of phosphatidylethanolamine catalyzed by PEMT,
which requires methionine (Cole et al., 2012). PC has an important
role to secrete triglyceride of liver as VLDL (Kulinski et al., 2004). Several
studies have shown that CDD impairs synthesis of PC and reduces secre-
tion of liver triglycerides, such as VLDL, resulting in the accumulation of
liver triglycerides (Li and Vance, 2008) and fatty liver (Setoue et al.,
2008; Raubenheimer et al., 2006; Kashireddy and Rao, 2004). The re-
sults of our study suggest that taurine added to a CDD exacerbates
liver fat accumulation and liver injury by impairing PC synthesis by
both the PEMT and CDP-choline pathways as CHKa and CHKb (Fig. 2).
In conclusion, a CDD causes increases in plasma Hcy and elevated
indices of liver injury characterized by oxidative stress and fatty liver.
Taurine supplementation was unable to increase Hcy catabolism by
47R. Deminice et al. / Life Sciences 105 (2014) 43–47transsulfuration pathway and prevent perturbations caused by CDD.
Also, taurine added to CDD results in decreased gene expression of
PEMT, CHKa, and CHKb, enzymes involved in PC formation, which has
a key role in secretion of liver triglycerides, such as VLDL, and fatty
liver progression. More studies are necessary to understand the effects
of taurine supplementation on CDD-induced HHcy and fatty liver.
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